"Orphan Drug Production" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.
| Descriptor ID |
D009965
|
| MeSH Number(s) |
J01.576.655.750.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Orphan Drug Production".
Below are MeSH descriptors whose meaning is more specific than "Orphan Drug Production".
This graph shows the total number of publications written about "Orphan Drug Production" by people in this website by year, and whether "Orphan Drug Production" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Orphan Drug Production" by people in Profiles.
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
-
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8.
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.